BetterLife Pharma Net Income
| BETRF Stock | USD 0.04 0 6.98% |
As of the 15th of February 2026, BetterLife Pharma shows the Risk Adjusted Performance of 0.0502, downside deviation of 11.74, and Mean Deviation of 8.24. BetterLife Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for BetterLife Pharma, which can be compared to its peers. Please confirm BetterLife Pharma variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if BetterLife Pharma is priced correctly, providing market reflects its regular price of 0.04 per share. As BetterLife Pharma appears to be a penny stock we also recommend to validate its total risk alpha numbers.
BetterLife Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BetterLife Pharma's valuation are provided below:BetterLife Pharma does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BetterLife |
BetterLife Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BetterLife Pharma's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BetterLife Pharma.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in BetterLife Pharma on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding BetterLife Pharma or generate 0.0% return on investment in BetterLife Pharma over 90 days. BetterLife Pharma is related to or competes with Mosaic Immunoengineerin. BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the t... More
BetterLife Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BetterLife Pharma's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BetterLife Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.74 | |||
| Information Ratio | 0.0448 | |||
| Maximum Drawdown | 52.18 | |||
| Value At Risk | (16.33) | |||
| Potential Upside | 22.58 |
BetterLife Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BetterLife Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BetterLife Pharma's standard deviation. In reality, there are many statistical measures that can use BetterLife Pharma historical prices to predict the future BetterLife Pharma's volatility.| Risk Adjusted Performance | 0.0502 | |||
| Jensen Alpha | 0.4431 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0463 | |||
| Treynor Ratio | 0.2257 |
BetterLife Pharma February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0502 | |||
| Market Risk Adjusted Performance | 0.2357 | |||
| Mean Deviation | 8.24 | |||
| Semi Deviation | 8.64 | |||
| Downside Deviation | 11.74 | |||
| Coefficient Of Variation | 1975.78 | |||
| Standard Deviation | 12.12 | |||
| Variance | 146.87 | |||
| Information Ratio | 0.0448 | |||
| Jensen Alpha | 0.4431 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0463 | |||
| Treynor Ratio | 0.2257 | |||
| Maximum Drawdown | 52.18 | |||
| Value At Risk | (16.33) | |||
| Potential Upside | 22.58 | |||
| Downside Variance | 137.91 | |||
| Semi Variance | 74.59 | |||
| Expected Short fall | (13.56) | |||
| Skewness | 0.8641 | |||
| Kurtosis | 1.44 |
BetterLife Pharma Backtested Returns
BetterLife Pharma appears to be out of control, given 3 months investment horizon. BetterLife Pharma secures Sharpe Ratio (or Efficiency) of 0.0461, which signifies that the company had a 0.0461 % return per unit of risk over the last 3 months. By analyzing BetterLife Pharma's technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please makes use of BetterLife Pharma's Risk Adjusted Performance of 0.0502, mean deviation of 8.24, and Downside Deviation of 11.74 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BetterLife Pharma holds a performance score of 3. The firm shows a Beta (market volatility) of 2.67, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BetterLife Pharma will likely underperform. Please check BetterLife Pharma's maximum drawdown and the relationship between the semi variance and day typical price , to make a quick decision on whether BetterLife Pharma's price patterns will revert.
Auto-correlation | -0.32 |
Poor reverse predictability
BetterLife Pharma has poor reverse predictability. Overlapping area represents the amount of predictability between BetterLife Pharma time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BetterLife Pharma price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current BetterLife Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, BetterLife Pharma reported net income of (12.16 Million). This is 103.56% lower than that of the Healthcare sector and 117.36% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.13% higher than that of the company.
BetterLife Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BetterLife Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BetterLife Pharma could also be used in its relative valuation, which is a method of valuing BetterLife Pharma by comparing valuation metrics of similar companies.BetterLife Pharma is currently under evaluation in net income category among its peers.
BetterLife Fundamentals
| Return On Equity | -44.17 | |||
| Return On Asset | -4.05 | |||
| Current Valuation | 12.42 M | |||
| Shares Outstanding | 90.1 M | |||
| Shares Owned By Insiders | 8.41 % | |||
| Price To Book | 13.65 X | |||
| Gross Profit | (22.81 K) | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.16 M) | |||
| Cash And Equivalents | 14.41 K | |||
| Total Debt | 34.56 K | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (11.2 M) | |||
| Earnings Per Share | (0.12) X | |||
| Beta | 1.62 | |||
| Market Capitalization | 9.49 M | |||
| Total Asset | 1.16 M | |||
| Net Asset | 1.16 M |
About BetterLife Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BetterLife Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BetterLife Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BetterLife Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in BetterLife OTC Stock
BetterLife Pharma financial ratios help investors to determine whether BetterLife OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BetterLife with respect to the benefits of owning BetterLife Pharma security.